These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16305437)

  • 1. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.
    Ramsay EC; Dos Santos N; Dragowska WH; Laskin JJ; Bally MB
    Curr Drug Deliv; 2005 Oct; 2(4):341-51. PubMed ID: 16305437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety.
    Franco MS; Oliveira MC
    Anticancer Agents Med Chem; 2019; 19(1):17-28. PubMed ID: 29692263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities.
    Chiu GN; Wong MY; Ling LU; Shaikh IM; Tan KB; Chaudhury A; Tan BJ
    Curr Drug Metab; 2009 Oct; 10(8):861-74. PubMed ID: 20214582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances of cocktail chemotherapy by combination drug delivery systems.
    Hu Q; Sun W; Wang C; Gu Z
    Adv Drug Deliv Rev; 2016 Mar; 98():19-34. PubMed ID: 26546751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving combination cancer therapy: the CombiPlex
    Tolcher AW; Mayer LD
    Future Oncol; 2018 Jun; 14(13):1317-1332. PubMed ID: 29363994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.
    Dicko A; Mayer LD; Tardi PG
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1329-41. PubMed ID: 21118030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging cancer biology and the patients' needs with nanotechnology-based approaches.
    Fonseca NA; Gregório AC; Valério-Fernandes A; Simões S; Moreira JN
    Cancer Treat Rev; 2014 Jun; 40(5):626-35. PubMed ID: 24613464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.
    Liboiron BD; Mayer LD
    Ther Deliv; 2014 Feb; 5(2):149-71. PubMed ID: 24483194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Cancer Therapy Using Multifunctional Liposomes.
    Jain A; Tiwari A; Verma A; Saraf S; Jain SK
    Crit Rev Ther Drug Carrier Syst; 2020; 37(2):105-134. PubMed ID: 32865902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
    Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
    Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.
    Patankar NA; Pritchard J; van Grinsven M; Osooly M; Bally MB
    Clin Cancer Res; 2013 Feb; 19(4):865-77. PubMed ID: 23303216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs.
    Gidwani B; Vyas A
    Biomed Res Int; 2015; 2015():198268. PubMed ID: 26582104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing combination chemotherapy by controlling drug ratios.
    Mayer LD; Janoff AS
    Mol Interv; 2007 Aug; 7(4):216-23. PubMed ID: 17827442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.
    Wadler S; Schwartz EL
    Cancer Res; 1990 Jun; 50(12):3473-86. PubMed ID: 1692761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
    Zucker D; Barenholz Y
    J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revolutionizing technologies of nanomicelles for combinatorial anticancer drug delivery.
    Jo MJ; Jin IS; Park CW; Hwang BY; Chung YB; Kim JS; Shin DH
    Arch Pharm Res; 2020 Jan; 43(1):100-109. PubMed ID: 31989478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.
    Yingchoncharoen P; Kalinowski DS; Richardson DR
    Pharmacol Rev; 2016 Jul; 68(3):701-87. PubMed ID: 27363439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.